

Extended-Release Drugs Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights

*The Business Research Company's
Extended-Release Drugs Global Market
Report 2025 – Market Size, Trends, And
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, November 24, 2025

/EINPresswire.com/ -- [Extended-Release Drugs](#) Market Growth Forecast:
What To Expect By 2025?

The market size for extended-release drugs has been experiencing fast-paced growth over the past few years. Its value is projected to rise from \$63.11 billion in 2024 to \$69.63 billion in 2025, marking a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic

period can be credited to enhanced patient compliance, the prevalence of chronic diseases, improved efficacy, patent protection strategies, and biodegradable implants.

“

Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors

”

*The Business Research
Company*

The market size of extended-release drugs is projected to experience a swift expansion in the upcoming years, expectedly reaching up to \$111.26 billion in 2029 with a compound annual growth rate (CAGR) of 12.4%. This anticipated surge during the forecasted period is majorly due to the introduction of personalized medicinal opinions, patient-specific drug creation, an escalating count of lifestyle-related illnesses, the practice of drug

revamping, and worldwide availability of extended-release treatment options. The forecasted timeline is set to witness dominant trends such as pharmaceutical inventions, progress in drug delivery systems, breakthroughs in nanotechnology, the applicability of 3D printing in drug composition, utilization of artificial intelligence, and emphasis on environmental sustainability.

Download a free sample of the extended-release drugs market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp>

The Business
Research Company

The Business Research Company



What Are Key Factors Driving The Demand In The Global Extended-Release Drugs Market?

The escalating prevalence of long-term health ailments is predicted to influence the expansion of the extended-release drug market. Chronic conditions are characterized as health issues that persist for at least a year and require ongoing medical assistance, hamper normal daily activities, or both. Heart disease, cancer, obesity, and diabetes stand as prime examples. Extended-release drug delivery systems are engineered to maintain a fairly steady concentration of medication within the body over an extended timeframe. It aids in preserving a regular therapeutic effect and negates the possible inconsistencies in drug levels occurring with immediate-release medications. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a United States-based National Library of Medicine, anticipated that by 2050, the population aged 50 years and above suffering from a minimum of one chronic disease will experience a 99.5% hike, escalating to 142.66 million. Thus, the escalating prevalence of chronic conditions is fueling the growth of the extended-release drug market.

Who Are The Leading Players In The Extended-Release Drugs Market?

Major players in the Extended-Release Drugs include:

- Pfizer Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi SA
- GlaxoSmithKline PLC
- AstraZeneca Plc
- Gilead Sciences Inc.
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Teva Pharmaceuticals Inc.

What Are Some Emerging Trends In The Extended-Release Drugs Market?

The emergence of product innovation is a prominent trend in the extended-release drug market. Mainstream companies within this market are making strides to maintain their market foothold by fostering innovative product development. To illustrate, Zydus Pharmaceuticals (USA) Inc., an American generic pharmaceutical firm, introduced the Topiramate extended-release capsules for epilepsy treatment in July 2022. The US Food and Drug Administration (USFDA) had pre-approved the company's distribution of Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. This positions Zydus Pharmaceuticals as the first in the nation to secure final approval and launch Topiramate extended-release capsules. Approvals for these extended-release tablets are given in two forms for patients dealing with partial onset or primary generalized tonic-clonic seizures.

Analysis Of Major Segments Driving The Extended-Release Drugs Market Growth

The extended-release drugs market covered in this report is segmented –

- 1) By Type: Sustained Release Drug, Controlled Release Drug
- 2) By Mode: Over-The-Counter, Prescription
- 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

- 1) By Sustained Release Drug: Matrix Systems, Coating Systems
- 2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

View the full extended-release drugs market report:

<https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report>

Which Region Is Expected To Lead The Extended-Release Drugs Market By 2025?

In 2024, the dominant region in the extended-release drugs market was North America, while the Asia-Pacific region is projected to show the most rapid growth in the forthcoming period. The regions that the report on the extended-release drugs market includes are North America, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the [Global Extended-Release Drugs Market 2025](#), [By The Business Research Company](#)

Extended Reality Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/extended-reality-global-market-report>

Drugs Of Abuse Doa Testing Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report>

Drugs For Benign Prostatic Hypertrophy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869162194>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.